Pfizer

Last week, TV host Dr. Mehmet Oz took on apple juice, declaring that the classic drink may be slowly poisoning America's children with arsenic. But the FDA and the juice companies have credibly refuted his claims. So was Dr. Oz's announcement meant to be a legitimate health warning, or just a cynical attempt to boost ratings?

A consumer advocacy group and professor of geriatric medicine are urging the Food and Drug Administration to yank the strongest dosage of a popular Alzheimer's medication from the market, because they're concerned that it is dangerous and ineffective. Donepezil, which is marketed by Eisai and...

With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.

Pfizer Inc. subsidiary Greenstone LLC recalled one lot of its Citalopram depression medicine and its prostate drug Finasteride because the wrong labels may have been put on the bottles, said the U.S. Food and Drug Administration. Greenstone said in a recall notice that bottles of Citalopram, a...

Japan's health ministry says it's continuing its suspension of pediatric vaccines made by Pfizer and Sanofi-Aventis, despite finding no connection between the vaccines and the deaths of four children. Both drugmakers are cooperating with the government and expect to be cleared.

Two pediatric vaccines have been suspended in Japan after the deaths of four children. Shares of Sanofi-Aventis and Pfizer, which make the drugs, have fallen in midday trading.

In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world's largest pharmaceutical company announced large research and development cuts were on the way.

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

Vaccine makers such as Pfizer are breathing easier now that the Supreme Court has ruled they can't be sued for defective vaccine designs. The majority opinion by Justice Antonin Scalia was unequivocal: Congress has barred lawsuits over the rare but unavoidable side effects of vital vaccines.

Pfizer beat Wall Street expectations by a slim margin as its profits nearly quadrupled, compared to a 2009 quarter hurt by big restructuring charges. Shares rose more than 5% even though the company warned that revenue is slowing and it plans to cut its workforce.